PharmGKB summary: clozapine pathway, pharmacokinetics

Pharmacogenet Genomics. 2018 Sep;28(9):214-222. doi: 10.1097/FPC.0000000000000347.

Authors

Caroline F Thorn¹, Daniel J Müller^{2

3}, Russ B Altman^{1

4}, Teri E Klein¹

Affiliations

¹ Departments of Biomedical Data Sciences.
² Pharmacogenetics Research Clinic, Centre for Addiction and Mental Health.
³ Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
⁴ Bioengineering and Genetics, Stanford University, Stanford, California, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antipsychotic Agents / adverse effects
Antipsychotic Agents / pharmacokinetics*
Antipsychotic Agents / therapeutic use
Clozapine / adverse effects
Clozapine / pharmacokinetics*
Clozapine / therapeutic use
Humans
Pharmacogenetics*

Substances

Antipsychotic Agents
Clozapine

Grants and funding

R24 GM061374/GM/NIGMS NIH HHS/United States